Research Article
Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial
Table 1
Comparison of the demographic data and general conditions of the enrolled subjects.
| | Variable | LH group
(N = 1101) | Control group
(N = 875) | value |
| | Age, years (median (IQR)) | 38.34 (10.00–89.00) | 37.74 (10.00–89.00) | 0.4572 | | Age group | 12–17 | 199 (18.07) | 105 (12.00) | 0.0082 | | 18–45 | 494 (44.87) | 474 (54.17) | | 46–70 | 358 (32.52) | 278 (31.77) | | >70 | 50 (4.54) | 18 (2.06) | | Gender | Male, N (%) | 543 (49.32) | 452 (51.66) | 0.3018 | | Drug combination | Yes, N (%) | 2 (0.18) | 0 (0.00) | 0.5063 | | Contact status | Close contacts, N (%) | 31 (2.82) | 35 (4.00) | 0.1455 | | Secondary close contacts, N (%) | 1070 (97.18) | 840 (96.00) | | Contact form | Living together, N (%) | 157 (14.26) | 29 (3.31) | <0.0001 | | Shared the same confined space, N (%) | 115 (10.45) | 240 (27.43) | | Dined together, N (%) | 93 (8.45) | 26 (2.97) | | Daily conversation, N (%) | 332 (30.15) | 138 (15.77) | | Rode in the same vehicle, N (%) | 76 (6.90) | 370 (2.63) | | Live on the same block, N (%) | 169 (15.35) | 23 (2.63) | | Via medical care, N (%) | 29 (2.63) | 45 (5.14) | | Others, N (%) | 130 (11.81) | 4 (0.46) | | Positive conversion time of RNA detection, days (median (IQR)) | 4.67 | 8.50 | 0.3078 |
|
|
